AimHighProfits Oct. 13 CORRECTION

JP Morgan announced their earnings at $1.02 EPS.  Over $24Billion in Revenue for the 3rd Quarter, 2011.  The market Reaction should be positive with this announcement.

6:59 AM EDT 
JP Morgan Chase & Co. (NYSEJPM) reported Q3 EPS of $1.02, $0.06 better than the analyst estimate of $0.96. Revenue for the quarter came in at $24.4 billion versus the consensus estimate of $23.73 billion.

On Other News out before the Bell:

Anadys Pharmaceuticals, Inc. (NASDAQ:ANDS) today released interim antiviral response and safety data from an ongoing Phase IIb study of setrobuvir in combination with pegylated interferon and ribavirin (P/R) in genotype 1 hepatitis C patients. Setrobuvir is the company’s direct-acting antiviral being developed for the treatment of chronic hepatitis C, or HCV.

“We are pleased with today’s data, which we believe demonstrate a compelling profile for setrobuvir in significantly more patients,” said Steve Worland, Ph.D., President and CEO of Anadys. “The antiviral response in patients who had failed prior treatment is a particularly encouraging benchmark of setrobuvir’s potency and high barrier to resistance. Coupled with a favorable safety profile to date, we believe today’s data position setrobuvir as a very attractive agent to be included in future DAA combination regimens.”

SOURCE: StreetInsider.com

0